Novo Nordisk buys drug candidate in billion dollar deal

The Danish pharmaceutical giant Novo Nordisk have made an agreement with KBP Biosciences to aqcuire the hypertension drug ocedurenone for up to 1.3 billion dollars, which corresponds to approximately 14 billion Swedish kronor.

“This deal is closely aligned with our strategic focus on expanding from our core in diabetes into other serious chronic diseases, including through novel drug modalities, to help many more patients living with unmet medical needs,” said Camilla Sylvest, executive vice president, Commercial Strategy & Corporate Affairs at Novo Nordisk, in a press release.

The drug candidate ocedurenone is currently being investigated in a phase-3 study in patients with uncontrolled hypertension and advanced chronic kidney disease. Novo Nordisk is now planning to carry out several phase-3 studies with the drug in other disease areas.

The acquisition is expected to be completed towards the end of this year and, according to Novo Nordisk, does not affect the profit outlook.

Artikeln är en del av vårt tema om News in English.

Kommentera en artikel
Utvalda artiklar


Sänd till en kollega